Pancreatic Cancer Research

ResearcherFourth Hospital of Hebei Medical UniversityActive in the last 2 years

Xin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7440-1075; OpenAlex author ID A5048500254. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: none · 2025: 2 papers

Papers 8

  1. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334374↗
  2. NCOA6 knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine. Co-author DOI 10.3724/abbs.2024221↗
  3. Nuclear receptor coactivator 6 (NCoA6) promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1002/cam4.6427↗
  4. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  5. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  6. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2874↗
  7. HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Co-author DOI 10.3390/cancers13246163↗
  8. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisabeth Heßmann · 6 shared papers, 2020–2025 · strength 0.79
  2. Jochen Gaedcke · 5 shared papers, 2020–2025 · strength 0.65
  3. Steven A. Johnsen · 5 shared papers, 2020–2025 · strength 0.65
  4. Ana P. Kutschat · 4 shared papers, 2021–2025 · strength 0.57
  5. Zeynab Najafova · 4 shared papers, 2021–2025 · strength 0.57
  6. Amro M. Abdelrahman · 3 shared papers, 2023–2025 · strength 0.45
  7. Mark Joseph Truty · 3 shared papers, 2023–2025 · strength 0.45
  8. Xiaowu Xu · 2 shared papers, 2023–2025 · strength 0.41
  9. Peng Li · 2 shared papers, 2023–2025 · strength 0.41
  10. Yuming Jia · 2 shared papers, 2023–2025 · strength 0.41
  11. Volker Ellenrieder · 3 shared papers, 2020–2025 · strength 0.39
  12. Feda H. Hamdan · 3 shared papers, 2021–2023 · strength 0.38
  13. Thomas L. Ekstrom · 2 shared papers, 2023–2025 · strength 0.32
  14. Jennifer A. Yonkus · 2 shared papers, 2023 · strength 0.27
  15. Joana E. Aggrey-Fynn · 2 shared papers, 2023 · strength 0.27
  16. Rondell Patrell Graham · 2 shared papers, 2023 · strength 0.27
  17. Roberto Alva‐Ruiz · 2 shared papers, 2023 · strength 0.27
  18. Stephan A. Hahn · 2 shared papers, 2023 · strength 0.27
  19. Jens Thomas Siveke · 2 shared papers, 2023 · strength 0.27
  20. Wuhan Yang · 1 shared paper, 2025 · strength 0.24
  21. Ye Zeng · 1 shared paper, 2025 · strength 0.24
  22. Shilpa Patil · 2 shared papers, 2020–2021 · strength 0.22
  23. Christina Parassiadis · 1 shared paper, 2025 · strength 0.19
  24. Danielle Marie Carlson · 1 shared paper, 2025 · strength 0.19
  25. Changfeng Song · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.